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Simple Summary: Post-translational modifications (PTM) of histone tails represent epigenomic
regulation of the chromatin landscape, influencing gene expression and the response to DNA damage.
This review focusses on cancer-associated roles of ubiquitin as a histone PTM, specifically in conjunction
with an E3 ubiquitin ligase cascade that results in the addition of a single ubiquitin (monoubiquitination)
to histone H2B at lysine 120 (H2Bub1). H2Bub1 has roles in chromatin accessibility important for
transcriptional elongation, the DNA damage response, cellular proliferation and developmental
transitions, including in stem cell plasticity. It has been implicated in inflammation and tumour
progression, with examples of its loss associated with a worse prognosis for patients with some
cancers. Many factors involved in the H2Bub1 interactome are well known cancer-associated proteins,
including p53, BRCA1 and components of the SWI/SNF remodelling complex. Increased knowledge
of H2Bub1 and its interactome offers new opportunities for therapeutic targeting of malignancy.
Abstract: Chromatin remodelling is a major mechanism by which cells control fundamental processes
including gene expression, the DNA damage response (DDR) and ensuring the genomic plasticity
required by stem cells to enable differentiation. The post-translational modification of histone H2B
resulting in addition of a single ubiquitin, in humans at lysine 120 (K120; H2Bub1) and in yeast at K123,
has key roles in transcriptional elongation associated with the RNA polymerase II-associated factor 1
complex (PAF1C) and in the DDR. H2Bub1 itself has been described as having tumour suppressive
roles and a number of cancer-related proteins and/or complexes are recognised as part of the H2Bub1
interactome. These include the RING finger E3 ubiquitin ligases RNF20, RNF40 and BRCA1, the guardian
of the genome p53, the PAF1C member CDC73, subunits of the switch/sucrose non-fermenting (SWI/SNF)
chromatin remodelling complex and histone methyltransferase complexes DOT1L and COMPASS,
as well as multiple deubiquitinases including USP22 and USP44. While globally depleted in many
primary human malignancies, including breast, lung and colorectal cancer, H2Bub1 is selectively enriched
at the coding region of certain highly expressed genes, including at p53 target genes in response to DNA
damage, functioning to exercise transcriptional control of these loci. This review draws together extensive
literature to cement a significant role for H2Bub1 in a range of human malignancies and discusses the
interplay between key cancer-related proteins and H2Bub1-associated chromatin remodelling.
Keywords: histone monoubiquitination; E3 ubiquitin ligases; RNF20; p53; BRCA1; CDC73; SWI/SNF;
transcriptional elongation; DNA damage
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1. Introduction
Post-translational modifications (PTMs) of core histone proteins H2A, H2B, H3 and H4 constituting
the nucleosome have driving roles in modulating the chromatin landscape in order to regulate
fundamental processes such as transcription and the DNA damage response (DDR). Examples of
histone PTMs include methylation, acetylation, phosphorylation, SUMOylation, proline isomerisation
and ubiquitination [1,2]. The addition of a single 76 amino acid (8.5 kDa) ubiquitin, monoubiquitination,
is one of the bulkier histone modifications [2,3]. A number of histone lysines (K) are monoubiquitinated
in the mammalian genome, including K13, K15, K119, K127 and K129 of histone H2A; K34, K120
and K125 of histone H2B; and K31 on histone H4 (reviewed in [4]). The two most well-known
mammalian histone monoubiquitination events occur on K119 of histone H2A (H2AK119ub1) linked
to the Polycomb Repressor Complex 1 (PRC1) [5] and K120 of histone H2B (H2Bub1), the latter being
the subject of this review. Interestingly, these events have opposing functions, with H2AK119ub1
associated with gene silencing and H2Bub1 frequently associated with active transcription [4–6].
A cascade of enzymatic events is responsible for monoubiquitination, involving an activating
ATP-dependent ubiquitin enzyme E1 of which humans have a few, a ubiquitin conjugating enzyme (E2)
of which humans have around 40, and a ubiquitin protein ligase (E3) of which humans have as many as
600–1000 [4,7,8]. The most prevalent of the E3 ubiquitin ligases are RING (really interesting new gene)
finger domain ligases of which the E3 complex RNF20/RNF40 is the main writer enzyme complex
responsible for catalysing H2Bub1 [1,9]. The H2Bub1 chromatin mark is erased by deubiquitinases
(DUBs) from the ubiquitin-specific protease (USP) sub-family of DUBs, including USP44 and USP22
(reviewed in [1,10–12]) (Figure 1).
The enzymatic cascade that writes H2Bub1 is invoked to enable association of the human RNA
polymerase II-associated factor 1 (PAF1) transcriptional complex with RNA polymerase II (RNA pol
II) to facilitate transcriptional elongation [13]. It is also required to facilitate the accumulation of
H2Bub1 at sites of double strand breaks (DSBs) where it functions as a scaffold or docking platform
for the recruitment of DNA repair factors [14]. H2Bub1 has also been linked to DNA replication in
yeast [15] and in both yeast and human cells, genomic stability through the maintenance of centromeric
chromatin [16]. While H2Bub1 itself has been described as having tumour suppressive properties,
a number of tumour suppressor proteins are also associated with H2Bub1-related processes including
RNF20, CDC73, BRCA1, p53 and members of the switch/sucrose non-fermenting (SWI/SNF) chromatin
remodelling complexes (also known as the BAF complexes) [17–20].
Global levels of H2Bub1 and/or its E3 ligase complex members RNF20 and RNF40, have been
investigated in numerous tumours using methods including immunohistochemistry and for RNF40
and/or RNF20, assessment of transcript levels and promoter hypermethylation. Dependent upon
tumour type, depleted global H2Bub1 levels have been shown to correlate with inflammatory processes
that may function as precursor events to tumorigenesis, in tumour progression and in some tumour
types have been correlated with a worse prognosis [21,22].
On the background of global loss of H2Bub1 in cancer cells, H2Bub1 is enriched at the coding
regions of highly expressed genes in response to DNA damage, including p53 gene targets and genes
involved in resistance to therapeutic drugs [23,24]. H2Bub1 therefore has a role in determining the fate
of cancer cells that may be amenable to therapeutic intervention. Further evidence for a key role in
determining cell fate is the role of H2Bub1 in the differentiation of stem cells, whether it be through
engaging with other histone PTMs via histone cross-talk, or the enzymes involved in writing and
erasing H2Bub1 [10,12]. H2Bub1 and its associated factors have also been linked to regulation of key
development pathways in plants, including seed dormancy/germination and flowering time, as well as
resistance to pathogen invasion [25–28]. It is clear that H2Bub1 has a significant role across species to
regulate important functions through the modulation of gene expression.
In this review we discuss the role of H2Bub1 in fundamental cellular processes including gene
transcription, the DDR and stem cell differentiation. We bring together the current literature on the
involvement of H2Bub1 across multiple different tumour types, including links recently established
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between H2Bub1 and inflammation. Lastly, we investigate the current state-of-play between H2Bub1
and members of its interactome complicit in the establishment and/or progression of malignancy.
Figure 1. The H2Bub1 interactome. H2Bub1 can be written (green plus symbol) by multiple writer
enzymes (E3 ubiquitin ligases) following an enzymatic ubiquitin cascade commencing with an E1
ubiquitin activating enzyme followed by an E2 ubiquitin conjugating enzyme. It can be removed
(red minus symbol) by numerous erasing deubiquitinases (DUBs) from the Ubiquitin-Specific Protease
(USP) sub-family. H2Bub1 interacts with a number of chromatin remodelling complexes and histone
chaperones. Numerous components of the H2Bub1 interactome function in more than one cellular
process, such as cyclin-dependent kinase 9 (CDK9) in stem cell plasticity and transcription, identified
in this schematic by matching colours. The H2Bub1 interactome continues to be elucidated and is
growing as new discoveries are made. Androgen receptor (AR); AT-Rich Interaction Domain 1B
(ARID1B); BRG1/BRM-associated factor (BAF250B); BRCA1-Associated RING Domain 1 (BARD1);
Breast Cancer Type 1 (BRCA1); Breast Cancer Type 2 (BRCA2); cyclin-dependent kinase 9 (CDK9);
estrogen receptor alpha (ERα); complex of proteins associated with SET1 (COMPASS); disrupter of
telomere silencing 1-like (DOT1L); facilitates chromatin transcription (FACT); Human Double Minute
2 (HDM2); X-ray Repair Cross Complementing 5 (Ku80, also known as XRCC5); RNA polymerase
II-associated factor 1 complex (PAF1C); Positive Transcription Elongation Factor-b (P-TEFb); tumour
protein 53 (p53); RNA polymerase II (RNA Pol II); RAD51 Recombinase (RAD51); RING Finger
Protein 20 (RNF20); RING Finger Protein 40 (RNF40); Spt-Ada-Gcn5-acetyltransferase (SAGA); Su(var)
3–9 (SET1, suppressor of position effect variegation), enhancer of zeste (E(z)), and trithorax (Trx);
SNF2 homologue, (SNF2H, also known as SMARCA5); Suppressor of Ty Homologue-6 (SUPT6H);
Switch/sucrose non-fermenting (SWI/SNF); transcription elongation factor II S (TFIIS); ubiquitin
conjugating enzyme E2 A (UBE2A); ubiquitin-conjugating enzyme E2 E (UBE2E1); Ubiquitin-Specific
Protease (USP); X-ray Repair Cross Complementing 4 (XRCC4). Created with BioRender.com.
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2. H2Bub1 and Transcriptional Elongation
Monoubiquitination isn’t the only histone PTM that occurs at K120 of histone H2B. Acetylation
at this site (H2BK120ac) written by the lysine acetyl transferase KAT3 is thought to act as a mark
of chromatin poised to enter the active state, highlighting the temporal acetylation/ubiquitination
switch working to achieve transcription [29]. H2Bub1 physically disrupts chromatin compaction,
creating a more open conformation accessible to transcription factors and other proteins and/or protein
complexes involved in activities such as DNA repair [30]. This is more than purely physical disruption,
as replacement of ubiquitin with the even bulkier molecule small ubiquitin-like modifier (SUMO),
does not result in the same functional effects [31]. K120 of histone H2B is physically located at the
interface of adjacent nucleosomes, making it possible that H2Bub1 has an impact on nucleosome
stacking that may affect nucleosome stability [30]. Chandrasekharan and colleagues demonstrated that
nucleosome stability increases in the presence of H2Bub1 during transcription and that this negatively
impacts upon cell growth [31], with a later study suggesting that this may be a modest effect [32].
H2Bub1 is enriched at the coding regions of highly expressed genes [24]. In response to stimuli
such as a hormone and/or a developmental signal or DNA damaging agent, cyclin-dependent kinase 9
(CDK9), part of the Positive Transcription Elongation Factor-b (P-TEFb) [33] complex, phosphorylates
both the H2Bub1 E2 enzyme UBE2A and Ser2 in the carboxy-terminal domain (CTD) of RNA
Pol II [12,34]. This creates a binding domain for WAC (WW Domain-Containing Adapter Protein
with Coiled-Coil) that directly links the main H2Bub1 E3 ligase complex RNF20/RNF40 to RNA pol
II [12,35]. In this co-transcriptional role with H2Bub1, CDK9 has been shown in yeast to be responsible
for releasing RNA pol II from promoter-proximal pausing, making it an important regulator of gene
expression [1,36,37]. Notably, RNA pol II promoter-proximal pausing has been implicated in the
suppression of transcription of antisense genes [38].
Both RNF20 and RNF40 have been shown to physically interact with subunits of the human
PAF1C (including the PAF1 subunit itself, CDC73 and CTR9) that associates with RNA Pol II, setting the
stage for interaction of all these factors that enable transcriptional elongation to proceed [39] (reviewed
in [1,10,12]) (Figure 1, Figure 2A). Enrichment of H2Bub1 occupancy at highly expressed genes has
been shown to correlate with the recruitment of Pol II, prior to the increase of mRNA expression
and to decrease once RNA Pol II has dissociated [24]. Examples of genes with enriched H2Bub1
include those that are transcriptionally driven by hormone receptors, specifically estrogen receptor
alpha (ERα) [22,40,41] important in some breast and ovarian cancers, and the androgen receptor (AR),
important in prostate cancer [42], as well as p53 target genes that function in the cellular response to
DNA damage [10,24] (Figure 2B).
To enable transcriptional elongation, H2Bub1 recruits the histone chaperone that facilitates
chromatin transcription (FACT) that works to remove the H2A-H2B dimer from the nucleosome,
therefore removing the physical block to RNA pol II (Figure 2A) [43]. A FACT subunit, Spt16, functions
with H2Bub1 to then enable nucleosome reassembly following RNA pol II transcriptional elongation [44].
These apparently opposing functions of H2Bub1 highlight its key roles in the kinetics of nucleosome
assembly and disassembly required during and post transcription.
H2Bub1 is also central in trans-histone crosstalk, recruiting histone methyltransferase complexes
that further direct chromatin configuration and gene expression [45–48]. The catalytic activity of the
disrupter of telomere silencing 1-like (DOT1L) histone methyltransferase that facilitates methylation
of histone H3 at K79 (H3K79me) at the proximal region of actively transcribed genes is stimulated by
H2Bub1 [49–54]. Loss of H3K79me2 has been correlated with genomic instability [55]. Another active
chromatin mark is histone H3K4 methylation that is catalysed by SET1, the methyltransferase subunit of
the complex of proteins associated with SET1 (COMPASS) after first being recruited by H2Bub1 [39,56,57].
Furthermore, Basnet and colleagues report an association between the phosphorylation of tyrosine
57 on histone H2A by casein kinase 2 (CK2) and H2Bub1 in yeast and mammalian cells. Loss of this
histone H2A phosphorylation event, either by mutation at the histone H2A tyrosine site or inhibition
of CK2, leads to loss of H2Bub1, H3K4me3 and H3K79me3, impacting on transcriptional elongation
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and likely involving the Spt-AdaGcn5 acetyltransferase (SAGA) chromatin modifying complex [58].
This is another example of how H2Bub1 functions in histone crosstalk. These patterns of trans-histone
cross-talk cement the importance of H2Bub1 as a central regulator of transcription (Figure 1).
Figure 2. H2Bub1 in transcriptional elongation. (A) Following stimuli such as DNA damage, hormones
or developmental signals, cyclin-dependent kinase 9 (CDK9) that is part of the Positive Transcription
Elongation Factor-b (P-TEFb) complex phosphorylates Ser2 in the carboxy-terminal domain of RNA
polymerase II (RNA pol II) depicted by a chain of circles, as well as the E2 ubiquitin conjugating
enzyme ubiquitin conjugating enzyme E2 A (UBE2A). This dual phosphorylation shown by red circles,
establishes a binding domain for the WW domain-containing adaptor with coiled-coil (WAC) and the E3
ubiquitin ligase complex RNF20/RNF40 that monoubiquitinates histone H2B at lysine 120 (H2Bub1,
ubiquitin shown as a purple circle). RNF20/RNF40 physically interacts with the PAF1 complex consisting
of CDC73, CTR9, LEO1, SKI8, RTF1 and PAF1 that associates with RNA pol II to establish transcriptional
elongation. The chromatin remodelling factor FACT is recruited by H2Bub1, and removes a H2B-H2A
dimer from the core nucleosome that takes away the physical block to RNA pol II, allowing it to move
through the nucleosome, facilitating gene expression (green arrow). (B) A number of transcription
factors have been associated with enriched H2Bub1 at target genes, including p53 (red lightning bolt
depicts DNA damage that activates this tumour suppressor), the estrogen receptor (ERα) and androgen
receptor (AR). ?? indicates as yet unknown transcription factors. Created with BioRender.com.
While being a clear enabler of transcriptional elongation, in certain circumstances H2Bub1 can also
impede it. At least in yeast, there would appear to be a positional effect determined by gene location
given that H2Bub1 at promoters of genes that aren’t expressed appear to inhibit the formation of
transcriptional complexes [59]. The H2Bub1 writer enzyme RNF20 has been demonstrated to obstruct
binding of the transcription elongation factor transcription elongation factor II S (TFIIS) to the PAF1C,
so blocking the ability to relieve stalled RNA pol II on chromatin [60]. In this way, RNF20 works to
selectively inhibit the transcription of pro-oncogenic genes located in condensed chromatin, supportive
of a tumour suppressor function for this E3 ligase. H2Bub1 occupancy is, therefore, complex and likely
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tissue, genomic position and contextually specific, as not all genes require H2Bub1 enrichment for
their expression [61]. One study combining RNA sequencing and Assay for Transposase Accessible
Chromatin (ATAC-seq) in fallopian tube epithelial cell lines suggested an association between loss of
H2Bub1 and a more open chromatin configuration [62]. In summary, H2Bub1 is a master regulator of
transcription, controlling gene expression in response to acute stimuli and developmental signals in a
context specific manner and occupying a central role in histone cross-talk directing gene expression.
3. H2Bub1 and the DNA Damage Response (DDR)
H2Bub1 accumulates after DNA damage at sites of DSBs as part of the cellular DDR [14,63,64].
Upon DNA damage, the ATM (ataxia telangiectasia mutated) kinase phosphorylates RNF20 and RNF40,
facilitating the recruitment of this E3 ligase complex to DSBs where it acts to catalyse H2Bub1 [14].
DNA damage-associated H2Bub1 then acts as a platform to recruit the chromatin remodelling factor SNF2H
and other proteins required for homologous recombination repair (HRR) including BRCA1, BRCA2 and
RAD51, as well as non-homologous end joining, including XRCC4 and Ku80 (Figures 1 and 3) [14,63,65].
Figure 3. H2Bub1 in the DNA damage response. In the presence of double strand breaks (DSBs),
ATM (ataxia telangiectasia mutated) phosphorylates (red circles) RNF20 and RNF40 that localise to DSBs
where they function as an E3 ligase complex to write H2Bub1 (purple circles). H2Bub1 acts as a platform
to attract proteins that work in both homologous recombination (HRR: BRCA1, BRCA2, RAD51,
SNF2H and additional proteins) and non-homologous end joining (NHEJ: XRCC4, Ku80 (XRCC5)
and additional proteins) to enable DNA repair. Created with BioRender.com.
Numerous factors that have a role in H2Bub1-related transcription also have a role in
H2Bub1-related DNA repair. One of these is the histone chaperone FACT complex subunit Spt16 that
binds to RNF20 to enable recruitment of SNF2H as well as the DNA repair proteins BRCA1 and RAD51
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at DSBs to initiate HRR [66]. RNF40 was shown to have a similar role and interaction with Spt16 at sites
of DSBs [67]. A number of the H2Bub1 DUBs have also been implicated in the DNA damage response
through modulation of chromatin, including USP11 [68], USP22 [69,70] and USP44 [71]. Furthermore,
the DOT1L histone methyltransferase known to engage in trans-histone cross-talk with H2Bub1 is
important for HRR at DSBs [72].
Global loss of H2Bub1 has been observed in cancer cell line models following treatment with DNA
damaging agents including doxorubicin, neocarzinostatin and cisplatin [14,23,24]. On the background
of this global loss, H2Bub1 is enriched in the coding regions of specific highly expressed genes,
including p53 target genes such as CDKN1A and MDM2 [23,24]. It is likely in these cases that many
genes that display enriched H2Bub1 following DNA damage are required for decisions regarding
cellular fate [23].
4. H2Bub1 and Cellular Proliferation in Cancer
It is well established that cellular proliferation is dependent upon access to chromatin to regulate
the expression of oncogenes and tumour suppressors that when aberrantly expressed can lead to
a malignant phenotype. Loss of H2Bub1 has been associated with tumour progression consistent
with a tumour suppressive function of this histone PTM [1,10,12]. The role of H2Bub1 in cellular
proliferation has been studied predominantly through manipulation of its key writer and eraser
enzymes. For example, siRNA (short interfering RNA) down-regulation of RNF20 and RNF40 has
been reported to inhibit proliferation of prostate cancer cells [42]. Of note, RNF40 has been implicated
in the control of key apoptotic genes in colorectal cancer cells [73].
RNF20 has also been identified as necessary for proliferation, both in vitro in mixed-lineage
leukemia (MLL)-rearranged human acute myeloid leukemia (AML) cell lines and in vivo, being
important for disease progression in a genetically engineered mouse model of AML [74]. RNF20 and
USP44 have different effects on the proliferation and migration of breast cancer cells dependent on
subtype, i.e., basal-like versus luminal [22]. H2Bub1-associated DUBs USP22, USP51 and USP27X have
been shown in vitro to be required for normal growth, with in vivo depletion suppressing tumour
growth in a mouse xenograft model of breast cancer cells [75]. Down-regulation of USP36 in lung
cancer cells has also been shown to negatively impact on cell proliferation [76]. A number of these
associations are discussed elsewhere in this review.
5. H2Bub1 is a Key Regulator of Developmental Transitions
5.1. H2Bub1 and Stem Cell Plasticity
Histone PTMs are important for maintaining stem cell self-renewal and the plasticity of stem cells,
as well as facilitates stem cell differentiation into different cell lineages [77–81]. H2Bub1 levels have been
shown to increase during the differentiation of embryonic stem cells (ESCs) and embryonal carcinoma
stem cells (ECSCs) [82], as well as in human mesenchymal stem cells (hMSCs) after differentiation
into osteoblasts and adipocytes [83]. Numerous components of the H2Bub1 interactome have been
implicated in the maintenance of stem cell pluripotency and differentiation, including the writers
RNF20 [82] and RNF40 [83], cyclin-dependent kinase CDK9 [83], the BAF250b (BRG1/BRM-Associated
Factor) subunit of the SWI/SNF chromatin remodelling complex [84], H2Bub1-interacting histone
methyltransferase complexes including COMPASS [85] and DOT1L [86–88], as well as the DUBs
USP22 [89–92] and USP44 [82,93]. As for DNA damage, H2Bub1 and many of its regulatory factors that
modulate chromatin play a central role in determining cellular fate as part of key signalling required
for differentiation. In the case of cancer stem cells that are linked with tumour initiation, relapse and
drug resistance, targeting specific components of the H2Bub1 interactome may offer new therapeutic
strategies for drug resistant malignancies [88,90,91,93].
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5.2. H2Bub Regulates Developmental Pathways and the Immune Response in Plants
Drawing parallels between the human and the plant world, H2Bub1 and the E2 and E3 ligases
involved in its writing have been shown to have major roles in the control of gene expression linked
to developmental and immune functions in a range of plant species. E2 and E3 ligases that write
H2Bub1 in Arabidopsis thaliana are pivotal in controlling expression of FLOWERING LOCUS C (FLC)
that is the main repressor of flowering, thus dictating flowering time [25,94]. H2Bub1 in Arabidopsis
has also been linked to the regulation of circadian clock genes [26]. Down-regulation of the E3 ligase
encoding flowering-related RING Protein 1 (FRRP1) in rice, Oryza sativa, has been shown to regulate
flowering time and yield potential, most likely through H2Bub1 [95]. Seed germination is another
key developmental transition for plants. H2Bub1 controlled by E3 ligases has been shown to control
the expression of genes involved in seed dormancy in Arabidopsis thaliana [27]. Further, variation in
monoubiquitination of histone H2A and H2B variants has been linked to the innate immune response
against fungal attack in rice, and H2Bub1 has been shown to have a role in defence against the fungus
Botrytis cinerea in tomato, again via its E3 ubiquitin ligases [28,96].
Considered together, H2Bub1 has a significant role in the plant ubiquitin chromatin landscape with
regulatory influence over the expression of genes in developmental programs including the circadian
clock, flowering time, seed dormancy and germination, as well as in pathogen defence. The role of
H2Bub1 spans multicellular eukaryotes and key cellular processes, establishing its importance as a
major epigenomic regulator of gene expression in both the animal and plant kingdom.
6. Global Loss of H2Bub1 in Human Malignancy
Global loss of H2Bub1 in primary tumours or early lesions has been detected using
immunohistochemistry by us and others across a range of malignancies. H2Bub1, RNF20 and/or RNF40
have been investigated in numerous cancer tissues, including breast [22,40,41,97,98], ovarian [62,99],
colorectal [21,97,100], lung [97,101], gastric [102], kidney [103] and parathyroid [18]. Where clear
numbers have been reported in publications, we have summarised this data; for H2Bub1 (Table 1)
and RNF20/RNF40 (Table 2). In some cancers, H2Bub1 loss by way of loss of RNF20 has been implicated
in an early inflammatory response, while in others it has been linked to progression of the tumour and
in some cases, a worse prognosis.
Table 1. H2Bub1 loss in primary tumours.
Tissue Type Cohort Size % H2Bub1 Loss Reference
Breast—normal mammary duct epithelial cells
(adjacent tissue) 8 0% [40]
Breast—benign tumour 18 0% [40]
Breast—cancer 64 67% [40]
Breast—cancer 34 97% [97]
Colon—normal mucosa 55 0% [100]




Gastric cancer (well differentiated) 23
4% ˆ [102]
30% ˆˆ
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Table 1. Cont.
Tissue Type Cohort Size % H2Bub1 Loss Reference
Gastric cancer (moderately differentiated) 55
13% ˆ [102]
40% ˆˆ
Gastric cancer (poorly differentiated) 81
21% ˆ [102]
77% ˆˆ
Lung—cancer 36 97% [97]
Lung—adenocarcinoma (well differentiated) 28 31% [101]
Lung—adenocarcinoma (moderately differentiated) 76 46% [101]













Parathyroid tumours (CDC73-associated) 11
55% ˆ [18]
45% ˆˆ
Where H2Bub1 data was reported both as total loss or weak to moderate immunohistochemical levels, it is identified
as follows: ˆ total loss of H2Bub1 (no nuclear H2Bub1 present detected by immunohistochemistry); ˆˆ weak to
moderate H2Bub1 detected by immunohistochemistry. HGSOC, High-grade serous ovarian cancer; STIC, Serous
Tubal Intraepithelial Carcinoma; FTE, fallopian tube epithelium.
Table 2. RNF20 and RNF40 loss in primary tumours.


























ˆ protein levels assessed by immunohistochemistry; ˆˆ gene transcript levels; ˆˆˆ total loss (immunohistochemical
score of 0); ˆˆˆˆ intermediate staining; * refers to lower RNF20 levels in malignant lung tissue versus normal lung
tissue. ** the remainder of this cohort was described as staining high for RNF40. HGSOC, High-grade serous
ovarian cancer; HCC, hepatocellular carcinoma.
6.1. H2Bub1 Loss is Associated with an Inflammatory Response that may Increase Risk of Developing Cancer
The ability to mount an appropriate inflammatory response is part of our key defence mechanisms
against pathogens and disease; however, it is when inflammation becomes chronic that problems can
arise, including acting as a trigger for tumorigenesis [105]. Chronic inflammation, such as that seen in
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inflammatory bowel disease (IBD) and ulcerative colitis (UC), is driven by inflammatory mediators
such as nuclear factor (NF)-κB and signal transducer and activator of transcription 3 (STAT3), cytokines
such as interleukin 6 (IL-6) and prostaglandins, and has been linked to an increased risk of developing
cancer [106–110]. Using a model of Rnf20 heterozygous mice to drive depleted H2Bub1, as well as
human samples of UC and colorectal cancer, Tarcic and colleagues have shown that loss of H2Bub1
creates a tumour promoting microenvironment in the colon centred on the chronic inflammatory
response [21]. The mechanism of up-regulation of genes associated with inflammation such as IL-6 and
IL-8 in conjunction with depleted H2Bub1 is through the pro-inflammatory cytokine tumour necrosis
factor alpha (TNF-α), itself mediated through NF-κB activation [110]. In non-cancerous epithelial cells
in this model, depletion of Rnf20 and as a result H2Bub1, fostered a pro-inflammatory transcriptional
response. Furthermore, gene expression of both RNF20 and RNF40, along with down-regulation
of H2Bub1, was identified in epithelial and stromal colonic tissue from patients with UC and was
inversely correlated with inflammatory cytokines IL6 and IL8 [21].
Studies comparing basal-like cells of triple negative breast cancer (TNBC) that are aggressive and
poorly differentiated tumours, with breast tumours of luminal origin with a more favourable prognosis
showed that TNBCs had expression of a greater number of inflammatory genes, including IL6 and
IL8 [22,111]. Down-regulation of RNF20 further increased the expression of IL6 and IL8 via NF-κB
signalling in basal-like breast cancer cells and depleted the repressive chromatin mark H3K9me3 at
their promoters [22]. In luminal breast cancer cells, however, RNF20 down-regulation was associated
with a decrease in expression of ER gene targets that drive proliferation and migration including PGR,
CXCL12 and FOXA1 [22]. This finding goes some way towards explaining the apparent opposite
roles of RNF20 and H2Bub1 in basal and luminal breast cancers, whereby RNF20 and H2Bub1 appear
to function in a tumour-suppressive role in basal-like breast cancer cells and be pro-oncogenic in
luminal breast cancer cells, driving tumorigenesis. Further supporting this phenomenon of a breast
cancer subtype-specific function of RNF40 and H2Bub1, Wegwitz and colleagues have shown that the
RNF40-H2Bub1 axis actually supports growth of HER2-positive (HER2+) breast cancers, both in vitro
and in vivo, via transcriptional activation of genes involved in maintenance of the actin cytoskeleton.
This important work highlights the opportunity for therapeutic intervention that targets RNF40 and/or
H2Bub1 in the HER2+ breast cancer subtype [112].
In addition to discoveries linking H2Bub1 and its ligation machinery to inflammatory conditions of
the colon with an increased risk of malignancy and developing TNBC, Hooda and colleagues discovered
modulation of H2Bub1 levels in pre-cursor cells of ovarian cancer with links to inflammatory genes [62].
Here, upon depletion of RNF20 and concomitant loss of H2Bub1 in fallopian tube epithelial cells,
the presumed site of origin of many high-grade serous ovarian cancers (HGSOCs), IL6 was elevated
and enhanced migration observed [62]. It is likely that additional tumour cell types will be discovered
to increase the production of inflammatory cytokines in response to depletion of RNF20 and H2Bub1,
contributing to a microenvironment conducive to initiating malignancy and/or driving tumorigenesis.
6.2. Global Loss of H2Bub1 Is an Early Event in Some Cancers
Two studies support that H2Bub1 loss is a very early event in ovarian tumorigenesis, with loss
detected in serous tubal intraepithelial carcinomas (STICs) now known to be the precursor lesion for
a large proportion of HGSOC [62,113,114], and also equally across all stages (I-IV) of HGSOC [99].
Dickson and colleagues demonstrated global loss of nuclear H2Bub1 in 77% (313 of 407) of HGSOC [99].
No correlation was made between loss of H2Bub1 and either progression free or overall survival.
Furthermore, no correlation was detected between the presence of a BRCA1 or BRCA2 mutation and
H2Bub1 loss. In the same tumour cohort, complete loss of RNF20 assessed using immunohistochemical
staining was seen in only 6% of tumours (26 of 424) and did not correlate with loss of H2Bub1, implying
that abrogation of RNF20 function does not explain the majority of H2Bub1 loss present in these
tumours. Of note, no HGSOC had both a BRCA1 mutation and RNF20 loss, suggesting that functional
abrogation of both of these E3 ligases in the same cell may be lethal [99].
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In apparent contrast to this earlier study of RNF20 immunohistochemistry in HGSOC, Hooda
and colleagues reported that over half of HGSOC in The Cancer Genome Atlas (TCGA; n = 579) are
heterozygous for RNF20 and that 36% were heterozygous for RNF40 [62]. RNF20 protein expression
would need to be interrogated in TCGA HGSOC samples to definitively correlate RNF20 and H2Bub1
in this cohort. A complete picture of the factors responsible for the maintenance of H2Bub1 in ovarian
and fallopian tube epithelia remains to be elucidated; however, it would appear that H2Bub1 E3
ubiquitin ligase writers, of which there are multiple [1,10] (Figure 1), can functionally substitute for one
another in some circumstances. Levels of RNF20 and RNF40 have also been reported to be lower than
normal tissue in testicular seminomas, with the suggestion that their loss occurs prior to development
of the invasive phenotype [115].
6.3. Global Loss of H2Bub1 Is Linked to Tumour Progression and a Worse Prognosis
One of the earliest immunohistochemical studies of global H2Bub1 levels in primary tumours
was conducted in breast cancer, where a clear increase in H2Bub1 loss was observed over tumour
progression, from no loss in normal adjacent tissue and benign tumours, to 67% loss in malignant
tumours and 84% loss in breast cancer metastatic deposits [40]. While this study did not analyse
tumours based on sub-type, Tarcic and colleagues have subsequently investigated H2Bub1 and its
ligation machinery in basal-like (TNBC) and luminal breast cancers [22]. Here, the correlation between
H2Bub1 levels and patient outcome was dependent on breast tumour subtype. For women with breast
tumours that were ER positive (ER+) and of a luminal subtype, higher levels of H2Bub1 correlated
with shorter survival times, while in TNBCs of a basal-like subtype, higher levels of H2Bub1were
associated with longer survival [22]. Basal-like tumours had lower H2Bub1 levels relative to other
breast sub-types, and are well known to have a worse prognosis. As already noted, in vitro experiments
interrogating cell migration and proliferation showed that depleting RNF20 that reduced H2Bub1
levels, acted to increase proliferation and migration of basal-like breast cancer cells, yet decreased
these functional endpoints in luminal-type cells. These growth patterns were recapitulated in a mouse
model, whereby down-regulation of RNF20 in basal-like cells resulted in faster growing mammary
tumours relative to control cells, while down-regulation of RNF20 in luminal type cells led to slower
growth than control cells [22]. Further in these preclinical models, metastases to the lung reflected the
rate of tumour growth, with down-regulation of RNF20 resulting in an increase of lung metastases
from basal-like cells only. Therefore at least in breast cancer, the role of RNF20 and H2Bub1 is highly
dependent on cell type of origin; in fact this role is dichotomous in basal-like versus luminal breast
cancer cells.
H2Bub1 loss has been strongly associated with a worse prognosis in colorectal cancer independent
of nodal stage; however, loss of H2Bub1 alone was not an independent prognostic marker [100].
Patients with gastric cancer that stain positively for H2Bub1 had a higher 5 year survival compared to
patients where H2Bub1 was lost; in fact, H2Bub1 was an independent prognostic factor for survival in
this cancer type [102]. Here, loss of H2Bub1 was increasingly associated with more poorly differentiated
tumours [102]. This was also the case for lung tumours and further, lung cancer patients whose
tumours were positive for H2Bub1 displayed a trend towards increased survival compared with
patients whose tumours had lost H2Bub1 [101]. Decreasing levels of tumour differentiation in parallel
with loss of H2Bub1 has also been reported in breast tumours, consistent with a role for H2Bub1 in
maintaining a differentiated phenotype [41]. Hahn and colleagues demonstrated global loss of H2Bub1
in familial and sporadic parathyroid tumours associated with mutation of a gene encoding a member
of the PAF1C, CDC73 [18]. Benign parathyroid tumours with wild-type CDC73 did not demonstrate
loss of H2Bub1.
7. Cancer-Related Proteins and the H2Bub1 Interactome
The interplay between complexes and factors that regulate the epigenome and cancer-related
proteins is important for chromatin modelling and gene expression. Understanding this interplay,
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both in healthy cells and in malignancy where tumour suppressors are frequently mutant and/or
silenced is an emerging and intricate field. There is a growing list of cancer-related proteins, many of
which have a tumour suppressive function, that either interact with, or constitute the ubiquitin
ligation machinery of H2Bub1, including RNF20 and RNF40, p53, BRCA1, CDC73, members of the
SWI/SNF chromatin remodelling complex, members of histone methyltransferase complexes involved
in cross-talk with H2Bub1 including DOT1L and COMPASS, and numerous deubiquitinases including
USP22 and USP44 (Figure 1). Below we discuss a number of these interactors, including their genetic
or epigenetic abrogation in malignancy, and acknowledge that there are likely many more that remain
to be discovered.
7.1. RNF20 and RNF40 E3 Ubiquitin Ligases
The majority of reports in the literature describe RNF20 in a manner consistent with being
classified as a tumour suppressor; however, some reports suggest a pro-oncogenic activity. While the
RNF20/RNF40 complex is accepted as the main E3 ligase complex responsible for writing H2Bub1,
substrates other than K120 on histone H2B have been reported. For instance, RNF20 polyubiquitinates
the ErbB3 receptor binding protein Ebp1 [116] and ZSCAN4 (Zinc Finger and SCAN Domain Containing
4) that is involved in telomere maintenance, genomic stability and mouse embryonic stem cells [117].
The RNF20/RNF40 complex can also monoubiquitinate the motor protein Eg5, a protein belonging
to the kinesin-like family with roles in spindle dynamics and assembly associated with mitosis [118].
The rat orthologue of RNF40, Staring, polyubiquitinates the nervous system specific protein Syntaxin 1
marking it for proteasomal degradation [119].
In line with a tumour suppressive function, copy number loss of RNF20 has been reported in
HGSOC [62] and pre-invasive dysplastic airway lesions [120]. A low frequency of RNF20 and RNF40
mutations have been reported in colorectal cancer [121,122]. RNF20 and/or RNF40 transcript levels are
depleted in a number of malignant or pre-malignant tissues, including in colonic tissue from patients
with UC [21], in metastatic prostate cancer cells when compared with benign disease [123] and is lower
in testicular germ cell cancer seminoma relative to normal testis [115]. Hypermethylation of the RNF20
promoter has also been discovered in primary breast cancers, consistent with a tumour suppressive
role for RNF20 [98]. Indirectly, RNF20 may function in a tumour suppressive capacity to obstruct
the expression of oncogenes including MYC and FOS located in regions of compacted chromatin by
interfering with recruitment of TFIIS that would usually function to relieve stalled RNA pol II [60].
RNF20 does this by obstructing the interaction between TFIIS and PAF1C.
In apparent contrast and already discussed in this review, a pro-oncogenic role for RNF20 has
been reported in breast cancer cells of luminal, but not basal cell-type origin [22]. RNF20 also has
an oncogenic role in MLL fusions that drive aberrant gene expression in haematopoietic cells and
are initiators of leukemogenesis. H2Bub1 enrichment correlating with transcriptional elongation is
observed in MLL-fusion target genes [74]. Furthermore, in colorectal cancer, RNF40 has been reported
to promote inflammatory signalling through NF-κB signalling [124] and in hepatocellular carcinoma,
RNF40 has been shown in a large cohort (n = 130) to be almost equally expressed at high or low levels,
with higher levels correlating with a worse prognosis [104].
Considering more broadly the cellular turnover of RNF20 and the role of additional factors,
the HECT-domain E3 ubiquitin ligase Smad ubiquitin regulatory factor 2 (Smurf2) that itself has
tumour suppressive roles, polyubiquitinates RNF20, marking it for proteasomal degradation, and in
this way is linked in with the regulation of H2Bub1 [125]. The relationship between Smurf2 and RNF20
is likely the mechanism that accounts for the role of Smurf2 in regulating the chromatin landscape and
maintaining genomic stability [126]. It is also involved in determining levels of RNF20 available to
participate at sites of DSBs as part of the DDR [125].
RNF40 also has interaction partners, an important one being the histone chaperone human
Suppressor of Ty Homologue-6 (SUPT6H) that likely works in a functional complex with RNF40 and
RNF20 to control H2Bub1 levels [41]. All of SUPT6H, RNF20, RNF40 and ERα have been shown to
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form a complex together at phosphorylated Ser 2 on the carboxy-terminal domain (CTD) of RNA Pol
II [41]. This relationship provides a platform for estrogen modulation of the chromatin landscape,
driving transcriptional elongation of ERα target genes important for proliferation and differentiation
of the mammary epithelium. Like H2Bub1 levels, SUPT6H levels were shown to decrease over
the course of breast tumorigenesis, with more malignant breast tumours with a worse prognosis
demonstrating less SUPT6H and H2Bub1 [41]. In addition to association with ERα and regulation of
ER target genes, RNF20 and RNF40 have been shown to physically associate with the AR, with the
H2Bub1/RNF20/RNF40 axis implicated in AR-associated gene transcription and affecting the growth
of prostate cancer cells [42]. Of note, both RNF20 and RNF40 have been linked to the maintenance of
genomic stability [104,115,125,127].
7.2. p53 Associates with the E3 Ubiquitin Ligase RNF20
The tumour suppressor p53 is encoded by the most frequently mutated gene in human malignancy,
being mutated in over 50% of all cancers, and referred to as the guardian of both the genome and the
epigenome [128,129]. p53 has been shown to directly interact with RNF20 and furthermore, RNF20
and/or the RNF20/RNF40 complex have been identified as transcriptional co-activators at the promoters
of p53 target genes including CDKN1A (encoding p21), MDM2, and BBC3 (encoding PUMA) [17,130].
Loss of the RNF20/RNF40 complex correlated with depleted levels of H2Bub1 in the coding regions of
these genes and reduced transcript levels [24,130]. A recent study investigating H2Bub1 enrichment at
p53 target genes in p53 wild-type and gain-of-function (GOF) mutant cell line models showed absence
of enrichment in the presence of TP53 mutations [23]. It will be interesting to determine whether GOF
mutant p53 cells can drive tumorigenesis by mechanisms such as H2Bub1 enrichment and correlated
increased gene expression at GOF mutant p53 target genes.
Furthermore, while the oncoprotein Human Double Minute 2 (HDM2), also frequently referred to
in the literature as MDM2, is well known as both a p53 target gene and the RING domain E3 ubiquitin
ligase that polyubiquitinates p53 for degradation via the proteasome [131], it has also been reported to
function as an enzymatic writer for H2Bub1 [132]. This would appear to be; however, on free histone
H2B, and not when H2B is part of the native nucleosome core where the RNF20/RNF40 complex
dominates as the main E3 ubiquitin ligase for H2Bub1 [12,133].
7.3. CDC73 Is a Binding Partner of RNF20 and RNF40
CDC73 (Cell Division Cycle 73; also known as parafibromin) is a classic tumour suppressor
and core member of the human PAF1C [13]. It is also present in Drosophila (dCdc73) where it is
more commonly referred to as Hyrax [134] and in yeast (yCdc73) [135]. In humans, mutations in
CDC73 (also known as HRPT2, Hyperparathyroidism 2) are present in germline DNA of patients
with the inherited conditions Hyperparathyroidism Jaw Tumour Syndrome (HPT-JT; OMIM 145001)
and Familial Hyperparathyroidism (FIHP; OMIM 145000) [136] reviewed in [137]. Somatic CDC73
mutations are also observed in parathyroid carcinoma [138,139]. Surrogate detection of CDC73
mutations by nuclear loss of immunohistochemical staining for CDC73 (parafibromin) in parathyroid
neoplasms is a recognised diagnostic for HPT-JT and/or parathyroid cancer [140–144].
Using a yeast two-hybrid assay, CDC73 was shown to directly bind to both E3 ubiquitin ligases
RNF20 and RNF40 [18]. Furthermore, loss of nuclear CDC73 in primary parathyroid tumours as the
result of CDC73 mutation led to significant depletion of H2Bub1, suggesting that CDC73 functions as a
key protein associating the PAF1C with the ligase machinery that synthesises H2Bub1 [18]. It is likely
that global loss of H2Bub1 and the entailing abrogation of gene expression is a major mechanism by
which mutant CDC73 exerts its tumorigenic effect.
7.4. BRCA1-BARD1 Is an E3 Ubiquitin Ligase for H2Bub1
Germline mutations in BRCA1 are well known to increase the risk of developing breast and/or ovarian
cancer, with somatic mutations of this tumour suppressor also identified in sporadic tumours [145–151].
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The BRCA1 Associated RING Domain 1 (BRCA1-BARD1) heterodimer is one of a number of E3 ligase
complexes reported to write H2Bub1 [19]. In fact, BRCA1-BARD1 has been shown to ubiquitinate all core
histones and the histone variant H2AX [152]. Despite this clear function of the BRCA1-BARD1 complex
as a writer of H2Bub1, a large study previously discussed in this review that analysed primary HGSOC
characterised for BRCA1 mutation was unable to demonstrate any correlation between BRCA1 mutation
and loss of H2Bub1 [99]. Given that there are multiple E3 ligases/ligase complexes that write H2Bub1,
it is likely that these enzymes may be able to work in concert to compensate for loss of one in order to
maintain this important histone modification.
7.5. SWI/SNF Chromatin Remodelling Complexes, Including ARID1B/BAF250b
Initially discovered in yeast, the SWI/SNF complexes are members of the family of adenosine
triphosphate (ATP) dependent chromatin remodelling complexes [153,154]. There are almost 30 known
genes encoding subunits of the SWI/SNF complexes, comprised of three distinct complexes with
unique and overlapping subunits (canonical BAF (cBAF), polybromo-associated BAF (PBAF) and
non-canonical BAF (ncBAF) (reviewed in [155]). Around 20% of all human malignancies harbour
a mutation in a gene encoding a SWI/SNF complex member [155,156]. Members of the SWI/SNF
complex, including BAF155, BAF170, BRG1 and BRM were all shown to associate with H2Bub1 enriched
chromatin [20]. Furthermore, SWI/SNF was shown to be required for optimal transcriptional elongation
for genes reliant on RNF20 and H2Bub1 for their expression [20]. In this way, H2Bub1 appears to act as
a recruitment scaffold or docking platform for the SWI/SNF chromatin remodelling complex to ensure
optimal gene expression. Further demonstrating a key relationship between SWI/SNF and H2Bub1 is
the discovery that the SWI/SNF complex member BAF250b/ARID1b form part of an E3 ubiquitin ligase
complex along with elongin C (Elo C), Cullin-2 and Roc-1 to write H2Bub1 [157].
7.6. H2Bub1 Deubiquitinases—USP22 and USP44
Ubiquitin is erased from histone H2B by DUBs of which there are at least twelve, not all in the
mammalian setting, reported in the USP family that can perform this function—USP3 [158], USP7 [159],
USP11 [68], USP12 [160], USP15 [161], USP22 [162], USP27X [75], USP36 [76], USP44 [82,163], USP46 [160],
USP49 [164] and USP51 [75]. Many of these DUBs have previously been reviewed in the context of
erasing H2Bub1 [1,10,12], therefore the focus here will be on recent discoveries, and specifically on
USP22 and USP44.
USP22 is perhaps the most well studied of the H2Bub1-associated DUBs [165]. It has been implicated
as part of the “death-from-cancer” signature, a stem cell gene expression signature consisting of 11 genes
prognostic of rapid relapse and resistance to therapy in different solid tumours [92,166]. Expression of
USP22 has been associated with stemness in cancer. In addition to its links with H2Bub1, USP22 also has
non-histone substrates with important links to cancer. One of these is with the oncogene c-Myc where
USP22 has been reported to function as a DUB to increase c-Myc stability in breast cancer cell lines with
implications for the progression of this malignancy [167]. USP22 also been shown to deubiquitinate the
transcriptional regulator far upstream element (FUSE)-binding protein 1 (FBP1), directly affecting the
expression of p21 and impacting upon cell proliferation and tumorigenesis [168].
USP22 functions as a subunit of the SAGA chromatin modifying complex that is a complex
capable of mediating deubiquitination and acetylation of histone and non-histone substrates [162,169].
The deubiquitinating module within SAGA consists of USP22, ATXN7L3, ATXN7 and ENY2 [165,170].
In humans, this deubiquitinating SAGA module is co-located with H2Bub1 within actively transcribed genes
and is classified as a global transcriptional activator important for all RNA Pol II transcription [171,172].
USP22 has been associated with increased angiogenesis, cancer cell proliferation and metastasis, cisplatin
and irradiation resistance and DNA damage signalling [173]. Targeting of USP22 is being explored as
a cancer therapeutic [90,173]. Of particular interest, USP22 has recently been implicated as a regulator
of PD-L1, marking it as a potential key factor in immune evasion that facilitates tumorigenesis [174].
Additional evidence that USP22 is involved in the immune response is its opposing role with RNF20 in
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determining expression of the transcription factor FOXP3 (Forkhead box protein P3) that determines the
development and function of regulatory T (Treg) cells that are important for the maintenance of self-tolerance
and immune homeostasis [175].
Of note, USP44, co-operating with USP7, has also been identified as a DUB for FOXP3, linking
these DUBs to Treg cells and the immune response and flagging them as possible therapeutic targets
for malignancy [176]. Furthermore, USP44 has recently been implicated in the innate immune
response mounted against DNA viruses as a positive regulator of the Stimulator of Interferon Genes
(STING) protein [177]. USP7 has also been implicated in destabilisation of the HDM2/p53 axis that is
fundamentally important in malignancy [178].
In basal-like TNBCs, there is an inverse relationship between USP44 and RNF20/RNF40 with
USP44 being more highly expressed, concomitant with lower levels of H2Bub1 in these tumours [22].
In cell line models of basal-like TNBC, down-regulation of USP44 leading to higher levels of H2Bub1
showed decreased proliferation and migration; however, the opposite was true for proliferation in
luminal cell line models, highlighting the importance of consideration of cell type when determining
therapeutic targeting of the H2Bub1 interactome [22]. As noted earlier, USP44 has been identified at
sites of DSBs [71].
8. Conclusions
H2Bub1 is a key histone modification influencing fundamental cellular activities including
transcriptional elongation, the DDR and stem cell plasticity. It is increasingly recognised as a central
histone PTM given its influence and/or interactions with other chromatin remodelling complexes
such as COMPASS, DOT1L, SAGA and SWI/SNF. The association of H2Bub1 with a growing list of
cancer-related proteins affirms its clear connection to cancer. Changes in H2Bub1 enrichment levels
have been implicated at all stages of tumour progression, from early lesions to metastatic disease,
including association with inflammation that may increase the risk of developing malignancy in
some tissues.
The importance of H2Bub1 and its modifying enzymes is now clearly established in both normal
cellular processes and in malignancy, yet we do not have clear explanations regarding some apparent
anomalies. Enrichment of H2Bub1, or lack thereof, in gene bodies does not always correlate with
gene expression. In fact depletion of the main H2Bub1 writers RNF20 and RNF40 only influences the
expression of a subset of genes [61,98]. This may be explained by selective regulation based on H2Bub1
levels, with only those genes with low to moderate H2Bub1 enrichment affected [61]. The high level
of degeneracy or compensatory functions offered by multiple H2Bub1 writers and erasers likely also
plays a role in maintaining the necessary levels of H2Bub1 enrichment for the maintenance of healthy
tissue and during development.
Stimulus-specific gene expression, such as seen in p53 target genes in response to DNA damage,
appear to have a strong correlation with H2Bub1 enrichment [23,24]. This would also seem to be true
for hormonally stimulated gene expression, including genes relying on the transcription factors ERα
and the AR [40,42]. The dynamic nature of histone PTMs, and specifically H2Bub1 in rapid chromatin
remodelling, is likely crucial for the high-speed responses needed for expression of many of these genes.
This is likely also true in developmental programming, including in the differentiation of mesenchymal
and embryonic stem cells. Yet another complexity of H2Bub1 and its associated writers and erasers
discussed in this review is seen in the context of different cellular subtypes of malignancy, with clear
examples of opposing proliferative and migratory effects of manipulating H2Bub1 ligation machinery
in luminal versus basal-like breast cancers [22]. It would appear that H2Bub1 and its associated factors
can function as drivers of tissue specific transcription patterns associated with distinct cellular types.
Taken together, it is clear that the complexities of H2Bub1 and its associated machinery must
be considered in a context specific fashion. Continued expansion and elucidation of the H2Bub1
interactome offers new insights into cellular processes and extends our opportunities for therapeutic
targeting of malignancy based on the epigenome and ubiquitin chromatin modelling.
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